GO:0005161 platelet-derived growth factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005161 describes the molecular function of binding to a platelet-derived growth factor receptor (PDGFR), a receptor tyrosine kinase.
• PDGF ligands exist as disulfide-linked dimers that bind and activate PDGFR dimers, triggering receptor autophosphorylation and intracellular signaling.
• The two-subunit model of PDGFR explains how different PDGF isoforms selectively bind and activate receptor dimers.
• PDGFR binding is central to proliferation, migration, and survival signaling in mesenchymal and other cell types.
• Dysregulated PDGF/PDGFR binding and signaling are implicated in neoplastic disorders and idiopathic hypereosinophilic syndrome.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of PDGFR binding and signaling.
Description
Platelet-derived growth factor receptor binding (GO:0005161) is a molecular function defined as binding to a platelet-derived growth factor receptor (PDGFR). This interaction is the first step in a well-characterized signaling axis in which secreted PDGF ligands engage PDGFR tyrosine kinases on the cell surface, leading to receptor activation and downstream signal transduction. The function is essential for understanding how cells respond to PDGF family ligands and how this response is perturbed in disease. PDGF was originally purified from platelets and shown to bind specifically to target cells, establishing the concept of a receptor-mediated growth factor system. Subsequent work identified the PDGFR as a tyrosine kinase that is autophosphorylated upon ligand binding and transduces signals to control proliferation and other cellular programs. Because PDGFR binding is a nodal point for growth factor signaling, it is a major focus in cancer biology, fibrosis, and inflammatory disorders, and it is a validated target for small-molecule inhibitors. Researchers studying GO:0005161 aim to define which ligands bind which receptor dimers, how binding affinity and specificity are determined, and how these events can be modulated genetically or pharmacologically.
platelet-derived growth factor receptor binding At A Glance
| GO ID | GO:0005161 |
|---|---|
| GO term | platelet-derived growth factor receptor binding |
| Ontology | molecular_function |
| Synonym | PDGF; PDGFR binding; PDGF receptor binding; platelet-derived growth factor; platelet-derived growth factor receptor ligand |
| Definition | Binding to a platelet-derived growth factor receptor. |
| Major function | Mediates specific interaction between PDGF ligands and PDGFR tyrosine kinases, initiating receptor activation and downstream signaling. |
| Related receptor class | Receptor tyrosine kinases (PDGFR alpha and PDGFR beta). |
| Ligand class | PDGF family growth factors, typically disulfide-linked dimers. |
| Disease relevance | Neoplastic disorders and idiopathic hypereosinophilic syndrome. |
What Is GO:0005161?
In simple terms, GO:0005161 means the ability of a protein or molecule to physically bind to a platelet-derived growth factor receptor. The QuickGO definition states: Binding to a platelet-derived growth factor receptor. This molecular function is typically executed by PDGF ligands (such as PDGFA, PDGFB, PDGFC, and PDGFD) that interact with PDGFR alpha and/or PDGFR beta on the cell surface. The binding event is non-covalent and specific, and it initiates receptor dimerization and activation.
Why Is platelet-derived growth factor receptor binding Important in Cell Biology?
GO:0005161 is important because it defines the molecular recognition step that controls PDGF-dependent cellular signaling. Binding of PDGF to PDGFR activates the receptor's tyrosine kinase activity, leading to autophosphorylation and recruitment of signaling proteins that drive proliferation, migration, and survival. This function is conserved and central to normal development and tissue repair, but its dysregulation contributes to neoplastic disorders and other pathologies. Understanding the binding mechanism at atomic and cellular resolution informs the design of inhibitors and genetic models that can block or tune this interaction.
• Defines the initial molecular event in PDGF/PDGFR signaling, a major growth factor pathway.
• Controls activation of PDGFR tyrosine kinase and downstream signal transduction.
• Regulates cell proliferation, migration, and survival in many cell types.
• Is a validated target for small-molecule PDGFR inhibitors in neoplastic disorders.
• Is implicated in idiopathic hypereosinophilic syndrome and other PDGFR-driven diseases.
• Provides a mechanistic basis for understanding autocrine and paracrine growth loops in tumors.
• Enables structure-function studies of ligand-receptor specificity using the two-subunit model.
• Supports development of CRISPR models to test causality of PDGF/PDGFR binding in disease.
• Helps interpret genomic alterations in PDGF/PDGFR genes in cancer and inflammatory conditions.
• Guides pharmacological strategies to modulate PDGFR activity in precision medicine.
Molecular Mechanism of platelet-derived growth factor receptor binding
Ligand recognition and binding specificity
In simple terms: PDGF ligands are dimers that must fit specific PDGFR dimers like a key in a lock.
PDGF family ligands are disulfide-linked dimers that bind to PDGFR alpha and/or PDGFR beta with distinct specificities. The two-subunit model of the PDGFR explains how different PDGF isoforms selectively engage receptor dimers, thereby determining which cells respond to which ligand. Specific binding of PDGF to target cells was demonstrated early using radioligand binding assays, establishing the receptor-mediated nature of the interaction. This binding step is non-covalent and reversible, and it is the first committed step in receptor activation.
Receptor dimerization and activation
In simple terms: When PDGF binds, two receptor molecules pair up and switch on their enzymatic activity.
Ligand binding induces or stabilizes PDGFR dimerization, which brings the intracellular kinase domains into proximity and enables autophosphorylation. The PDGFR is a receptor tyrosine kinase, and its activation leads to phosphorylation of specific tyrosine residues that serve as docking sites for downstream signaling proteins. Purification of the PDGFR using anti-phosphotyrosine antibodies confirmed that ligand binding triggers receptor tyrosine phosphorylation. This activation step is a hallmark of PDGF receptor signaling and is required for most downstream biological responses.
Signal transduction downstream of PDGFR binding
In simple terms: Once the receptor is switched on, it sends signals inside the cell that tell it to grow or move.
Activated PDGFR transduces signals through multiple intracellular pathways that collectively regulate proliferation, migration, and survival. Williams (1989) reviewed the signal transduction mechanisms by which the PDGF receptor converts extracellular binding into intracellular second messengers and gene expression changes. Benito et al. (1993) described PDGF/tyrosine kinase receptor-mediated proliferation, linking receptor activation to cell cycle progression. These downstream events explain why PDGFR binding is a central node in growth control and why its dysregulation can drive disease.
Regulation and pharmacological modulation
In simple terms: The binding event can be blocked or tuned by drugs and by changes in receptor availability.
Small-molecule PDGFR inhibitors have been developed to block receptor kinase activity and are used in the treatment of neoplastic disorders. Stone et al. (2004) described PDGFR inhibition as a therapeutic strategy in idiopathic hypereosinophilic syndrome, demonstrating that interrupting PDGFR signaling can produce clinical benefit. Receptor availability, ligand concentration, and the presence of competing ligands all influence the net binding and activation state. Thus, GO:0005161 is not only a mechanistic function but also a druggable node in disease.
Key Genes Involved in GO:0005161 platelet-derived growth factor receptor binding
The following genes and proteins are directly or closely associated with platelet-derived growth factor receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDGFA | PDGF ligand that binds and activates PDGFR alpha | Studied for autocrine/paracrine growth signaling |
| PDGFB | PDGF ligand that binds PDGFR alpha and beta | Key ligand in fibroblast and mesenchymal signaling |
| PDGFC | PDGF ligand with selectivity for PDGFR alpha | Used to dissect ligand-receptor specificity |
| PDGFD | PDGF ligand with selectivity for PDGFR beta | Model ligand for PDGFR beta activation studies |
| PDGFRA | Receptor tyrosine kinase that binds PDGF ligands | Target for mutation and inhibitor studies |
| PDGFRB | Receptor tyrosine kinase that binds PDGF ligands | Implicated in hypereosinophilic syndrome and neoplasms |
| SRC | Downstream kinase activated by PDGFR signaling | Used to map signal transduction pathways |
| PIK3CA | PI3K subunit involved in PDGFR downstream signaling | Studied in proliferation and survival assays |
| PLCG1 | Phospholipase C gamma 1 activated downstream of PDGFR | Used to probe second messenger signaling |
| GRB2 | Adaptor protein recruited to activated PDGFR | Studied in receptor-proximal signaling complexes |
| STAT5A | Transcription factor activated by PDGFR signaling | Investigated in proliferation and survival |
| JAK2 | Kinase that can cooperate with PDGFR signaling | Studied in myeloproliferative contexts |
| FYN | Src-family kinase downstream of PDGFR | Used in phosphoproteomic studies |
| NCK1 | Adaptor protein linking PDGFR to cytoskeletal signaling | Studied in migration assays |
| PTPN11 | Phosphatase that modulates RTK signaling | Investigated as a regulator of PDGFR output |
| CBL | E3 ubiquitin ligase that regulates RTK turnover | Studied in receptor degradation and feedback |
| SHC1 | Adaptor protein that binds activated PDGFR | Used to map Ras-MAPK activation |
How Is platelet-derived growth factor receptor binding Regulated?
The platelet-derived growth factor receptor binding function is regulated at multiple levels, including ligand availability, receptor expression, and feedback desensitization. PDGF ligands are secreted and can act in autocrine or paracrine modes, so local ligand concentration directly affects receptor occupancy. Receptor levels are controlled by transcription, trafficking, and degradation, and activated receptors are subject to negative feedback through phosphatases and ubiquitin ligases. Pharmacological inhibitors can block the kinase activity that follows binding, effectively modulating the functional output of this molecular function. In disease contexts, genetic alterations that increase ligand or receptor abundance can amplify binding and downstream signaling, making this function a target for therapeutic intervention.
platelet-derived growth factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDGFRA | Neoplastic disorders with PDGFR pathway activation | PDGFRA knockout or point-mutation cell lines |
| PDGFRB | Idiopathic hypereosinophilic syndrome | PDGFRB knock-in or overexpression models |
| PDGFB | Autocrine growth signaling in tumors | PDGFB overexpression and ligand-binding assays |
| PDGFC | Ligand-specific PDGFR activation | PDGFC knockout and rescue models |
| PDGFD | PDGFR beta-driven proliferation | PDGFD overexpression and signaling readouts |
PDGFR binding in neoplastic disorders
Dysregulated PDGF/PDGFR signaling is implicated in a range of neoplastic disorders, and small-molecule PDGFR inhibitors have been developed as therapeutic agents. Because GO:0005161 defines the binding step that initiates receptor activation, alterations that increase ligand-receptor engagement can drive tumor cell proliferation and survival. Targeting this binding-dependent activation pathway is a rational strategy in cancers with PDGFR pathway dependency.
PDGFR binding in idiopathic hypereosinophilic syndrome
PDGFR inhibition has been shown to be an effective treatment strategy in idiopathic hypereosinophilic syndrome, a disorder in which aberrant PDGFR signaling drives eosinophil proliferation. This clinical example demonstrates that interrupting the PDGF/PDGFR axis at the level of receptor kinase activity can reverse a disease phenotype. It also highlights the importance of understanding the binding and activation mechanism for therapeutic design.
PDGFR binding in proliferative and fibrotic biology
PDGF/tyrosine kinase receptor-mediated proliferation is a well-described mechanism linking receptor binding to cell cycle progression. Signal transduction by the PDGF receptor controls programs that are also relevant to fibrosis and tissue remodeling. Thus, GO:0005161 is not only a cancer-relevant function but also a general mechanism in proliferative and reparative biology.
From platelet-derived growth factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDGFR binding abolish downstream signaling? | PDGFRA or PDGFRB knockout cell lines |
| Which residues are required for ligand binding? | Point-mutation knock-in of PDGFR binding interface |
| Can a disease-associated mutation enhance PDGFR activation? | Knock-in of mutant PDGFRA or PDGFRB |
| Where does PDGFR localize after ligand binding? | Tagged knock-in of PDGFR with fluorescent tag |
| Does ligand overexpression drive proliferation? | PDGF ligand overexpression models |
| Can pharmacological inhibition block PDGFR output? | Inhibitor treatment in wild-type and mutant cells |
How to Study the platelet-derived growth factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Specific ligand-receptor binding | Quantify PDGF binding to cells |
| Anti-phosphotyrosine immunoblot | Receptor tyrosine phosphorylation | Measure PDGFR activation |
| Phospho-signaling immunoblot | Downstream pathway activation | Map signal transduction |
| CRISPR knockout | Loss of gene function | Test requirement for PDGFR binding |
| CRISPR point mutation | Specific residue function | Dissect binding interface |
| CRISPR knock-in tag | Protein localization and interactions | Image PDGFR trafficking |
| Overexpression | Gain of function | Model ligand-driven proliferation |
| Inhibitor treatment | Acute pathway blockade | Validate therapeutic targeting |
Ligand-receptor binding assays
Direct binding assays using radiolabeled or fluorescently labeled PDGF ligands can quantify specific binding to target cells and measure affinity and competition. These assays established the original evidence that PDGF binds specifically to cell surface receptors. They remain useful for validating whether a genetic alteration changes binding capacity.
Phosphotyrosine and signaling readouts
Because PDGFR activation leads to tyrosine autophosphorylation, anti-phosphotyrosine immunoprecipitation and immunoblotting can measure receptor activation after ligand binding. Downstream signaling can be assessed by phospho-specific antibodies against effectors of the PDGFR pathway. These readouts connect the binding function to functional activation.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of PDGFR binding and signaling in isogenic backgrounds. Knockout of ligand or receptor genes can abolish the binding function, while knock-in of specific mutations can test structure-function hypotheses. These approaches are essential for distinguishing correlation from causation in PDGFR biology.
Pharmacological inhibition and rescue
Small-molecule PDGFR inhibitors can be used to acutely block receptor kinase activity and test whether a phenotype depends on PDGFR signaling. Rescue experiments with inhibitor-resistant receptor variants can further confirm on-target effects. This method is particularly valuable in disease models such as hypereosinophilic syndrome.
How CRISPR Can Be Used to Study GO:0005161 platelet-derived growth factor receptor binding
Knockout
CRISPR knockout of PDGF ligands or PDGFR genes can eliminate the platelet-derived growth factor receptor binding function and reveal which downstream phenotypes depend on this interaction. Knockout models are useful for testing whether a disease phenotype requires PDGFR signaling.
Point Mutation
Point mutations introduced by CRISPR can alter specific residues in the ligand or receptor to test binding specificity and activation mechanisms. Such models help define the structural determinants of the two-subunit receptor model.
Knock-in
Knock-in of disease-associated or tagged PDGFR variants allows study of mutant receptor behavior in a native genomic context. Tagged knock-in can also be used to track receptor localization after ligand binding.
Overexpression
Overexpression of PDGF ligands or receptors can model autocrine or paracrine loops that drive proliferation and transformation. These models are useful for testing whether increased binding capacity is sufficient to induce a phenotype.
How EDITGENE Supports platelet-derived growth factor receptor binding Research
Researchers studying platelet-derived growth factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor engagement, receptor activation, or downstream signaling. CRISPR-based models provide a rigorous way to test these hypotheses in isogenic cell backgrounds, and EDITGENE offers a comprehensive suite of services to support such studies.
Contact EDITGENE today to design your custom CRISPR model for platelet-derived growth factor receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Itga5 Knockout MOC2 Cell Line | EDJ-KQ59 | Mouse | 16402 | Details Get a Quote |
| Itga5 Knockout MC-38 Cell Line | EDJ-KQ92 | Mouse | 16402 | Details Get a Quote |
| IL1R1 Knockout HEK293 Cell Line | EDJ-KQ568 | Human | 3554 | Details Get a Quote |
| LYN Knockout HEK293 Cell Line | EDJ-KQ574 | Human | 4067 | Details Get a Quote |
| PDGFD Knockout HEK293 Cell Line | EDJ-KQ723 | Human | 80310 | Details Get a Quote |
| VEGFD Knockout HEK293 Cell Line | EDJ-KQ763 | Human | 2277 | Details Get a Quote |
| ITGB3 Knockout HEK293 Cell Line | EDJ-KQ818 | Human | 3690 | Details Get a Quote |
| ERN1 Knockout HEK293 Cell Line | EDJ-KQ1003 | Human | 2081 | Details Get a Quote |
| PDGFA Knockout HEK293 Cell Line | EDJ-KQ1197 | Human | 5154 | Details Get a Quote |
| PDGFB Knockout HEK293 Cell Line | EDJ-KQ1198 | Human | 5155 | Details Get a Quote |
| PDGFC Knockout HEK293 Cell Line | EDJ-KQ1199 | Human | 56034 | Details Get a Quote |
| PTPRJ Knockout HEK293 Cell Line | EDJ-KQ3021 | Human | 5795 | Details Get a Quote |
| VEGFA Knockout HEK293 Cell Line | EDJ-KQ17674 | Human | 7422 | Details Get a Quote |
| PDGFRB Knockout HEK293 Cell Line | EDJ-KQ17677 | Human | 5159 | Details Get a Quote |
| ITGA5 Knockout HEK293 Cell Line | EDJ-KQ17703 | Human | 3678 | Details Get a Quote |
Displaying Records 1 To 15 Of 68 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About platelet-derived growth factor receptor binding
What is platelet-derived growth factor receptor binding?
It is the molecular function defined by GO:0005161, in which a molecule binds to a platelet-derived growth factor receptor, typically a PDGF ligand engaging PDGFR alpha or beta.
What genes are involved in platelet-derived growth factor receptor binding?
Key genes include PDGFA, PDGFB, PDGFC, PDGFD, PDGFRA, and PDGFRB, which encode the ligands and receptors that mediate this binding.
What is the GO ID for platelet-derived growth factor receptor binding?
The GO ID is GO:0005161.
How does PDGF binding activate the receptor?
Binding induces receptor dimerization and autophosphorylation of the PDGFR tyrosine kinase, which then recruits downstream signaling proteins.
What diseases are linked to PDGFR binding and signaling?
Neoplastic disorders and idiopathic hypereosinophilic syndrome are linked to dysregulated PDGFR signaling.
What is the two-subunit model of the PDGF receptor?
It is a model explaining how different PDGF isoforms bind and activate receptor dimers with distinct specificities.
How can I study PDGFR binding in the lab?
Common methods include radioligand binding assays, anti-phosphotyrosine immunoblotting, and CRISPR-based genetic perturbation.
What CRISPR models are available for PDGFR research?
Knockout, point mutation, knock-in, and overexpression models can be generated to test ligand-receptor function and signaling.
Are there drugs that target PDGFR binding or signaling?
Yes, small-molecule PDGFR inhibitors have been developed and used in neoplastic disorders and hypereosinophilic syndrome.
Why is PDGFR binding important for cancer research?
Because it initiates a growth factor signaling pathway that can drive proliferation and survival, making it a therapeutic target.
Conclusion
GO:0005161, platelet-derived growth factor receptor binding, defines the molecular recognition event that initiates PDGF/PDGFR signaling. This function is central to proliferation, migration, and survival programs and is implicated in neoplastic disorders and idiopathic hypereosinophilic syndrome. Understanding its mechanism through binding assays, signaling readouts, and CRISPR models provides a foundation for therapeutic targeting and for interpreting disease-associated genetic alterations.
References
- 1. Bowen-Pope DF et al.. 1984. Platelet-derived growth factor.. Clin Endocrinol Metab 13(1):191-205 PMID: 6327124
- 2. Hart CE et al.. 1990. Platelet-derived growth factor receptor: current views of the two-subunit model.. J Invest Dermatol 94(6 Suppl):53S-57S PMID: 2161888
- 3. Huang JS et al.. 1982. Platelet-derived growth factor. Specific binding to target cells.. J Biol Chem 257(14):8130-6 PMID: 6282873
- 4. Daniel TO et al.. 1985. Purification of the platelet-derived growth factor receptor by using an anti-phosphotyrosine antibody.. Proc Natl Acad Sci U S A 82(9):2684-7 PMID: 2581254
- 5. Roskoski R Jr. 2018. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.. Pharmacol Res 129:65-83 PMID: 29408302
- 6. Stone RM et al.. 2004. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.. Semin Oncol 31(2 Suppl 6):12-7 PMID: 15175999
- 7. Benito M et al.. 1993. Platelet derived growth factor/tyrosine kinase receptor mediated proliferation.. Growth Regul 3(3):172-9 PMID: 8220110
- 8. Williams LT. 1989. Signal transduction by the platelet-derived growth factor receptor.. Science 243(4898):1564-70 PMID: 2538922
